What is High-Throughput Screening?

In a drug discovery process, high-throughput screening (HTS) is a technique for screening and profiling a large number of biological modulators and effectors against a specific target. HTS assays accelerate drug discovery by screening large compound libraries, including combination chemistry, genomics, protein, and peptide libraries. The goal of HTS is screening at rates that can exceed thousands of compounds per day or week. Today, the use of high-throughput screening technologies significantly speeds up drug discovery and reduces costs.

Service Overview

HTS refers to the massive testing of hundreds or thousands of small molecules during the hit identification process of drug discovery. Ace Therapeutics has a high-quality small molecule compound library for ocular diseases to support our HTS services, and meets the needs of global customers in ophthalmic product development through our advanced technology platform and extensive capabilities.

At the Ace Therapeutics center for ophthalmic small molecule drug discovery, we provide state-of-the-art and flexible HTS services in various assay formats (biochemical, cellular, biophysical) using 96, 384 or 1536 well formats to help clients worldwide find optimal new chemical starting points for drug development. Benefit from our ocular disease small molecule compound library, our talented scientists can provide you with access to small molecule leads targeting your project-specific ocular disease targets and modalities to suit your budget and program needs. In addition, Ace Therapeutics is happy to perform HTS for you if you are willing to contribute your own compound library for ocular diseases.

Case Design for Retinal Eye Diseases Small Molecule Compounds HTS Services

We use eye disease small molecule compounds to perform high-throughput screening for retinal eye diseases. The library contains tens of thousands of small molecule compounds with chemical and pharmacological characteristics.

Throughout the analysis, the in vitro monolayer permeability of retinal endothelial cells (HREC) was examined using the cellular cubstrate impedance sensing (ECIS) system. HRECs (approximately 8000 cells/well) were seeded into fibronectin-coated 384-well plates and grown for 24 hours before adding each of the compounds (10 μM) from the ocular disease small molecule drug library to the wells. Finally, possible drug targets and potential small molecule compounds are identified based on colorimetric, fluorescence, or luminescent signal-based whole-well averages, as well as single-cell-based high-content imaging (brightfield or fluorescence).

Explore Our Capabilities

• Design and development of HTS assays for small molecule compounds in eye diseases: Ace Therapeutics' expert team designs biochemical benchtop assays into HTS assays in multi-well plate format as needed.
• Target identification: We have a target library subset containing the most common pharmacologically characterized target classes for ocular diseases.
• Comprehensive hit screening: We have a small molecule compound library for ocular diseases containing more than 13,000 unique pharmacological entities, which can be used for comprehensive hit identification analysis.
• Small molecule purity and mass determination: Combined with an LC-MS platform, the purity and molecular weight of molecules can be determined.

What Sets Us Apart?

• A comprehensive and integrated approach to early  ophthalmic small-molecule drug discovery.
• High-quality and large ocular diseases small molecule compounds library.
• Extensive knowledge of high throughput screening assay development solutions.
• High-quality starting point for ocular disease targets and drug development.
• Personalized and customized innovative scientific research services.

Ace Therapeutics provides extensive technical support for the development of ophthalmic products for customers around the world. Our high-throughput screening services for small molecule compounds in ocular diseases significantly save the cost of drug discovery and greatly improve the chance of success. Our experts in high-throughput screening will represent you throughout the process of accessing small molecule leads for your project-specific ocular disease targets. If you are interested in our services or want to know more details, please feel free to contact us. We look forward to witnessing your success with you.

• Virtual Screening Services for Small Molecule Ophthalmic Drug Development
• Ligand-Based Virtual Screening Services for Small Molecule Ophthalmic Drug Development
• Fragment-Based Virtual Screening Services for Small Molecule Ophthalmic Drug Development
• Phenotype-Based Virtual Screening Services for Small Molecule Ophthalmic Drug Development
• Structure-Based Screening Services for Small Molecule Ophthalmic Drug Development
• Computer-Aided Screening Services for Small Molecule Ophthalmic Drug Development
• Ocular Diseases Small Molecules Compound Library

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit